Navigation Links
Unraveling a stomach cancer puzzle

It started several years ago with the observation that a large group of seemingly unconnected genes were behaving differently in patients with stomach cancer. Now a multi-national research team led by the Melbourne Branch of the Ludwig Institute for Cancer Research (LICR) has joined the proverbial dots and identified a potential new target for stomach cancer therapy, according to a paper published today in the prestigious Nature Medicine journal.

The paper's first author, LICR's Dr. Brendan Jenkins, says that this single study has made several substantial contributions to the understanding of Stat3, the protein linking those 'genes behaving badly' and central to development, tissue equilibrium and the immune system. "We showed that, in mice, hyperactive Stat3 shuts down a vital controller of stomach cell growth, called TGF beta, and this allows cancer formation, and this mechanistic link is a world-first. Also, the gene differences identified in human stomach cancers are similar to those we would predict if the same thing, Stat3 hyperactivity shutting down TGF, happens in humans. So this is also the first time a connection between stomach cancer and this signaling pathway has been made."

Team leader Dr. Matthias Ernst, also from LICR, says that these basic research findings may one day impact directly on the treatment of stomach and other cancers. "We've demonstrated that by lowering Stat3 hyperactivity we can suppress stomach cancer formation, importantly without affecting Stat3's other important roles in the body. Add to that the evidence suggesting that Stat3 is also involved in breast, head and neck, and prostate cancers, and we have a compelling case for investigating the development of therapies that target Stat3."


'"/>

Source:Ludwig Institute for Cancer Research


Page: 1

Related biology news :

1. Unraveling the mysteries of poison
2. Unraveling the viral mechanism
3. Unraveling where chimp and human brains diverge
4. Salmonella survives better in stomach due to altered DNA
5. Prehistoric origins of stomach ulcers uncovered
6. Viral DNA sequence a possible trigger for breast cancer
7. Enzyme, lost in most mammals, is shown to protect against UV-induced skin cancer
8. Its not all genetic: Common epigenetic problem doubles cancer risk in mice
9. Columbia research lifts major hurdle to gene therapy for cancer
10. Combination therapy boosts effectiveness of telomere-directed cancer cell death
11. Mitochondrial DNA mutations play significant role in prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems ... seamlessly log work hours, for employers to make sure the right employees are actually ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
Breaking Biology Technology: